Catalyst Pharmaceuticals Inc (CPRX)

Form DEFM14A - Definitive proxy statement relating to merger or acquisition

Form 4 - Statement of changes in beneficial ownership of securities

Form PREM14A - Preliminary proxy statements relating to merger or acquisition

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the...

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.

As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January...

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the...